Despite receiving permission for the vaccine about six months ago, Johnson and Johnson (J&J) India’s launch and exports from the nation in conjunction with Biological E appear to remain in limbo.
The impasse over the indemnity clause in India and reduced demand for J&J’s own vaccine globally has derailed the company’s plans, officials aware of the development told Mint. The companies had not officially given a timeline for the launch, but according to government officials J&J and Biological E were planning to make available 8 million doses of the vaccine by October.